UGN-103 for Bladder Cancer
(UTOPIA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This Phase 3, single-arm, multicenter study will evaluate the efficacy and safety of UGN-103, a novel formulation of UGN-102, instilled in the urinary bladder of patients with low-grade non-muscle invasive bladder cancer (LG-NMIBC).
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss your specific medications with the trial team to get a clear answer.
Is UGN-103 safe for humans?
What makes the drug UGN-103 unique for treating bladder cancer?
What data supports the effectiveness of the drug UGN-103 for bladder cancer?
Research on similar treatments like UGN-101 and UGN-102, which are also mitomycin-containing gels, shows promising results in treating low-grade urothelial carcinomas by increasing the time the drug stays in contact with the cancer cells, leading to better outcomes. These treatments have been effective in managing similar types of cancer, suggesting potential effectiveness for UGN-103 in bladder cancer.13457
Who Is on the Research Team?
Sunil Raju, MBBS
Principal Investigator
UroGen Pharma
Are You a Good Fit for This Trial?
This trial is for patients with a type of bladder cancer called low-grade non-muscle invasive bladder cancer (LG-NMIBC). Participants must have had at least one prior episode, may have multiple tumors or a tumor larger than 3 cm, and should show signs of early or frequent recurrence. They need normal blood counts and no high-grade disease in recent tests. Patients must consent to follow the study rules.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive UGN-103 instilled in the urinary bladder once weekly for 6 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment, with evaluations every 3 months
What Are the Treatments Tested in This Trial?
Interventions
- UGN-103
Find a Clinic Near You
Who Is Running the Clinical Trial?
UroGen Pharma Ltd.
Lead Sponsor